PCRX News and Press, Pacira BioSciences Inc. From 05/07/24

-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the first quarter of...

TAMPA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 10:30 AM ET on Tuesday, May 14, 2024 in New York. Live audio of the ev...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results after the close of the U.S. markets on Tuesday May 7, 2024. Following the release, the company will host a live conference call and webcas...

2024-04-23 18:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-04-09 11:15:02 ET RBC Capital analyst issues UNDERPERFORM recommendation for PCRX on April 9, 2024 10:00AM ET. The previous analyst recommendation was Underperform. PCRX was trading at $28.44 at issue of the analyst recommendation. The overall analyst consensus : BU...

2024-04-09 11:15:02 ET Wedbush analyst issues BUY recommendation for PCRX on April 9, 2024 10:00AM ET. The previous analyst recommendation was Buy. PCRX was trading at $28.44 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...

TAMPA, Fla., April 02, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 23 rd Annual Needham Virtual Healthcare Conference at 8:00 AM ET on Monday, April 8, 2024. Live audio of the virtual even...

-- PCRX-201 is the first gene therapy product candidate to receive RMAT designation for osteoarthritis -- -- Designation supported by encouraging preliminary data from 72-patient Phase 1 study -- -- 52-Week Data Accepted for Presentation at OARSI 2024 and 104-week data to be sub...

2024-03-08 10:21:57 ET More on Teva Pharmaceutical Teva And Alvotech: Simlandi Approval Opens New Generic Market Opportunities Teva Pharmaceutical: I Need To See Top-Line Growth Return Before Starting A Position A Review Of Teva's Prospects UroGen falls as Te...